**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 65554

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Biliary complications in recipients of living donor liver transplantation: A single-centre study**

Guirguis RN *et al*. Biliary complications following RT-LDLT

Reginia Nabil Guirguis, Ehab Hasan Nashaat, Azza Emam Yassin, Wesam Ahmed Ibrahim, Shereen A Saleh, Mohamed Bahaa, Mahmoud El-Meteini, Mohamed Fathy, Hany Mansour Dabbous, Iman Fawzy Montasser, Manar Salah, Ghada Abdelrahman Mohamed

**Reginia Nabil Guirguis, Ehab Hasan Nashaat, Azza Emam Yassin, Wesam Ahmed Ibrahim, Shereen A Saleh, Ghada Abdelrahman Mohamed,** Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt

**Mohamed Bahaa, Mahmoud El-Meteini, Mohamed Fathy,** Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt

**Hany Mansour Dabbous, Iman Fawzy Montasser, Manar Salah,** Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt

**Author contributions:** Guirguis RN, Nashaat EH, Yassin AE, Ibrahim WA, Saleh SA, Bahaa MM designed the research; Bahaa MM, El-Meteini M, Fathy M performed the surgical procedures; Guirguis RN, Dabbous HM, Montasser IF, Salah M performed the perioperative management; Guirguis RN participated in the acquisition of data; Guirguis RN, Nashaat EH, Yassin AE, Ibrahim WA, Saleh SA, Mohamed GA participated in the analysis and interpretation of the data; Guirguis RN, Saleh SA, Bahaa MM, Mohamed GA revised the article critically for important intellectual content; Mohamed GA wrote the manuscript.

**Corresponding author: Ghada Abdelrahman Mohamed, MD, Lecturer,** Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, El-Khalifa El-Maamon Street, Abbassia, Cairo 11591, Egypt. ghadaabdelrahman@med.asu.edu.eg

**Received:** March 9, 2021

**Revised:** May 2, 2021

**Accepted: October 24, 2021**

**Published online:**

**Abstract**

BACKGROUND

Biliary complications (BCs) after liver transplantation (LT) remain a considerable cause of morbidity, mortality, increased cost, and graft loss.

AIM

To investigate the impact of BCs on chronic graft rejection, graft failure and mortality.

METHODS

From 2011 to 2016, 215 adult recipients underwent right-lobe living-donor liver transplantation (RT-LDLT) at our centre. We excluded 46 recipients who met the exclusion criteria, and 169 recipients were included in the final analysis. Donors’ and recipients’ demographic data, clinical data, operative details and postoperative course information were collected. We also reviewed the management and outcomes of BCs. Recipients were followed for at least 12 mo post-LT until December 2017 or graft or patient loss.

RESULTS

The overall incidence rate of BCs including biliary leakage, biliary infection and biliary stricture was 57.4%. Twenty-seven (16%) patients experienced chronic graft rejection. Graft failure developed in 20 (11.8%) patients. A total of 28 (16.6%) deaths occurred during follow-up. BCs were a risk factor for the occurrence of chronic graft rejection and failure; however, mortality was determined by recurrent hepatitis C virus infection.

CONCLUSION

Biliary complications after RT-LDLT represent an independent risk factor for chronic graft rejection and graft failure; nonetheless, effective management of these complications can improve patient and graft survival.

**Key Words:** Biliary complications; Living donor liver transplantation; Retrospective analysis; Bile leak; Biliary stricture; Risk factors; Mortality; Graft rejection

Guirguis RN, Nashaat EH, Yassin AE, Ibrahim WA, Saleh SA, Bahaa M, El-Meteini M, Fathy M, Dabbous HM, Montasser IF, Salah M, Mohamed GA. Biliary complications in recipients of living donor liver transplantation: A single-centre study. *World J Hepatol* 2021; In press

**Core Tip:** We included 169 right lobe living-donor liver transplantation recipients in this retrospective study. The overall incidence rate of biliary complications including biliary leakage, biliary infection and biliary stricture was 57.4%. Twenty-seven (16%) patients experienced chronic graft rejection. Graft failure developed in 20 (11.8%) patients. A total of 28 (16.6%) deaths occurred during follow-up. Biliary complications were an independent risk factor for the occurrence of chronic graft rejection and failure; however, mortality was determined by unresolved recurrent hepatitis C virus infection. In conclusion, biliary complications represent an independent risk factor for chronic graft rejection and graft failure; nonetheless, effective management of these complications can improve patient and graft survival.

**INTRODUCTION**

Liver transplantation (LT) is a life-saving therapeutic modality for patients with end-stage hepatic disease[1]. Despite considerable progress in LT surgical performance and peri-operative management, post-LT biliary complications (BCs) remain a considerable cause of morbidity, mortality, increased cost, and graft loss[2,3].

Living-donor liver transplantation (LDLT) is a well-established substitute to deceased-donor LT (DDLT)[4,5]. LDLT has potential advantages over DDLT, such as lower cost, superior graft vitality, shorter cold ischemia time, and lower prevalence of steroid-resistant graft rejection[6]. However, it has been reported that LDLT is related to higher post-LT morbidity, hospitalization rates and duration of stay. This is mainly referred to the higher incidence rate of BCs in LDLT ranging from 10% to 67% compared to DDLT[7-9], which could be attributed to the technically challenging biliary reconstruction during LDLT[9]. Technical skilfulness is mandatory to reduce the incidence of BCs[10], and the most critical key step is to maintain the blood supply to the biliary ducts in donor surgery[11].

Post-LT BCs include biliary strictures (BSs), biliary leaks (BLs), and biliary infection. There are two types of BLs post-LDLT: Anastomotic and cut surface BLs[12,13]. BLs occur commonly at the T-tube insertion site and less frequently at the anastomosis site[14]. Most BLs occur within the first post-transplant month and are mostly related to inadequate surgical skills or biliary duct ischemia[15].

BSs are the most common BC, accounting for 40% of BCs following LT. Like BLs, BSs are more prevalent post-LDLT when compared to DDLT, mostly due to the more technically challenging biliary anastomosis in LDLT due to the small-sized ducts requiring multiple biliary anastomoses[7,16]. BSs typically present after one month post-LT; in addition, they can be anastomotic or non-anastomotic[12]. Anastomotic strictures account for approximately 80% of post-LT BSs and commonly occur in LDLT and at the anastomotic site[7,17]. Non-anastomotic strictures account for approximately 10%-25% of post-LT BSs[18]. BSs are mainly linked to surgical skills, patients with small-sized ducts, donor-recipient bile duct size mismatch, longer operative time, total ischemia time, local ischemia, chronic rejection, older donor age, donor and recipient gender matching and initial disease recurrence like primary sclerosing cholangitis (PSC)[2,3,19,20].

Duct-to-duct anastomosis (DDA) has developed into the preferred biliary reconstruction method due to its benefits of a shorter total operative time, less incidence of post-operative infections, more physiological enteric functions and the enablement of access to the biliary tree in case of complications. Roux-en-Y hepaticojejunostomy (RYHJ) is performed in the case of re-transplantation or short or diseased bile ducts[21]. However, diversity in the results regarding the superiority of both of the two biliary reconstruction and suturing techniques is still present[3,8,15,22].

Similarly, the use of biliary drainage remains controversial[10]. The post-LT stent represents a method for biliary tract decompression, as well as the facilitation of postoperative cholangiography[22]. However, this technique is predisposed to BL at the entry site and thus has become less commonly used[14]. Also, temporary internal biliary stents may be applied to cross the anastomosis site[19]; however, it has been reported that the incidence of BCs may increase with this technique[23].

There is considerable overlap in the diagnostic and therapeutic modalities in patients with post-LT BCs. Frequently used diagnostic modalities include abdominal ultrasonography, computed tomography scan, magnetic retrograde cholangiopancreatography (MRCP), magnetic resonance imaging, percutaneous transhepatic cholangiography (PTC) and endoscopic retrograde cholangiopancreatography (ERCP). Currently, the preferred imaging method for the biliary tract is MRCP; it provides a guide for further interventional approaches[14].

In the case of isolated deranged liver functions post-LT, it is crucial to make an accurate diagnosis of other parenchymal hepatic diseases such as acute or chronic rejection, drug-induced hepatotoxicity, recurrence of primary cholestatic disease or viral hepatitis to further apply the appropriate management plan. Liver biopsy is a conclusive diagnostic procedure for these patients[4,7].

The management of BCs depends on a multidisciplinary approach including endoscopic, percutaneous and surgical interventions. Currently, ERCP is the preferable first-line therapeutic modality, especially in cases of DDA[4,17]. The success rate of this technique is variable, ranging from 51% to 100%[24]. If ERCP fails, PTC can be tried; also, it is the preferred therapeutic modality in cases of RYHJ. Surgical intervention is a last option for BCs management[2,20]. However, the optimal strategy for managing post-LT BCs remains undefined.

Based on the published literature, BC causes significant morbidity following LDLT. If not managed properly, it leads to cholestasis, progressive bridging fibrosis, secondary biliary cirrhosis and eventually graft failure. Hence, we aimed to investigate its impact on chronic graft rejection, graft failure and mortality.

**MATERIALS AND METHODS**

***Study design***

This retrospective cohort study was conducted at Ain Shams Centre for Organ Transplantation, Ain Shams Specialized Hospital, Cairo, Egypt, from January 2011 to December 2016. This study was performed according to the ethical guidelines of the Declaration of Helsinki and was approved by the ethical review board of the Faculty of Medicine, Ain Shams University (No. FMASU MD 187/2016), which waived the requisite of informed consent owing to the retrospective nature of the study.

During the study period, 215 adult recipients underwent right lobe-LDLT (RL-LDLT) at our centre. We excluded 46 patients who met the exclusion criteria, and 169 recipients were enrolled in the final analysis. We included cirrhotic patients who met the transplantation criteria of our institution [a Child-Pugh score of ≥ 7 and model for end-stage liver disease (MELD) score of ≥ 15]. Patients with hepatocellular carcinoma (HCC) were enrolled if they met the Milan criteria, defined as a single lesion ≤ 5 cm or up to three lesions of ≤ 3 cm each with the absence of vascular invasion and extra-hepatic metastases[25]. We excluded patients with cholestatic hepatic diseases [primary biliary cirrhosis (PBC) or PSC] and early postoperative mortality and patients lost on follow-up (Figure 1).

Donors’ and recipients’ demographic data, clinical data, operative details and postoperative course information were collected. We also reviewed the management and outcomes of BCs. Recipients were followed for at least 12 mo post-LT until December 2017 or graft or patient loss.

***Study definitions***

The following BCs and their management were recorded from data files:

**BL:** Clinically suspected due to the existence of bile in the surgical drains or the presence of an intra-abdominal biloma and confirmed by imaging studies.

**Biliary infection:** Clinically suspected due to fever, abdominal pain, rigours, biochemical cultures and elevated inflammatory markers, including levels of C-reactive protein.

**BS:** Clinically suspected due to jaundice, pruritus, and elevated levels of serum bilirubin and/or alkaline phosphatase and confirmed by imaging studies as a narrowing at any site of the biliary tree whether at an anastomotic or non-anastomotic site with proximal dilatation.

***Diagnosis of other clinical outcomes***

**Graft failure:** Confirmed by histological evidence as graft cirrhosis, the need for re-transplantation because of graft failure and/or allograft-associated mortality.

**Chronic ductopenic graft rejection:** Proven by liver biopsy.

**Recurrent hepatitis C virus (HCV) infection:** Proven by high viral load, elevated transaminases and liver biopsy.

***Institutional surgical technique for right lobe living donor liver transplantation***

A right-lobe graft was used without the middle hepatic vein by the piggyback technique. Biliary anastomosis was done by DDA with an end-to-end interrupted style using absorbable polydioxanone (PDS-II; Ethicon) 6-0 sutures[26]. A ductoplasty was conducted if one duct was approximately twice the size of the other. A routine external biliary stent was inserted for three months post-operation. Three drains were placed postoperatively: in the right subphrenic space, the right Morrison’s pouch and at the cut surface of the graft. Internal biliary stents were used selectively if indicated. Arterial reconstruction was described previously[27]. The ratio of graft weight to recipient body weight was used to assess the relation of the graft size for recipients[27]. The accepted ratio was 1.2 ± 0.2%. All recipients had the same ABO blood group as the donors.

***Statistical methods***

Data were analysed using IBM© SPSS© Statistics version 23 (IBM© Corp., Armonk, NY) and MedCalc© version 18.2.1 (MedCalc© Software bv, Ostend, Belgium). Non-parametric numerical variables were presented as medians and interquartile ranges, whereas between-group differences were analysed using the Mann-Whitney test and, in the case of paired data, the Wilcoxon signed-rank test. Parametric numerical data were shown as mean ± standard deviation, and between-group differences were analysed using a *t*-test and, in the case of paired data, a paired *t*-test. Nominal variables were shown as number and percentage, and differences were analysed using Pearson’s chi-squared test or Fisher’s exact test. Ordinal data were analysed using the chi-squared test for trend. Multivariable binary logistic regression analysis was used to define the independent risk factors. Univariable time-to-event analysis was done using the Kaplan-Meier method. Cox proportional hazard regression analysis was used for multivariable time-to-event analysis. Two-sided *P* values of < 0.05 were considered statistically significant.

**RESULTS**

This study included 169 adult RL-LDLT recipients. At the time of operation, the mean age of the recipient was 50 ± 8 years, and 150 (88.8%) were male. The indications for LT were HCC [60 (35.5%)] and liver cirrhosis because of HCV [148 (87.6%)], hepatitis B virus (HBV) [5 (3%)], HCV and HBV coinfection [4 (2.4%)], and other aetiologies including vascular, autoimmune, and cryptogenic cirrhosis [12 (7.1%); Tables 1,2].

Prior to LT, 33 (19.52%) patients were HCV RNA negative, and 136 (80.46%) were HCV RNA positive. Thirty-one (18.3%) patients received antiviral treatment prior to LT. Forty-one (24.3%) patients experienced recurrent HCV infection, which was resolved in 37 (90.2%) patients (Table 1). Before the direct-acting antivirals (DAA) era, a Peg-interferon alfa-2a/Ribavirin (Peg-IFN/RBV) regimen was used for eligible patients, whereas after the availability of DAA therapy, sofosbuvir/daclatasvir ± RBV, sofosbuvir/simeprevir and ledipasvir/sofosbuvir regimens were used.

The majority of grafts had one or two ducts [both *n* = 78 (46.2%)], and the majority of patients needed one anastomosis [109 (64.5%)]. One to two stents were used in the majority of grafts [71 (42%) and 79 (46.7%), respectively; Table 1].

Fourteen (8.3%) patients experienced arterial complications; 12 patients had hepatic artery thrombosis (HAT), and two patients had hepatic artery stenosis (HAS; Table 1). In case HAT was detected not beyond two weeks post-LT, re-exploration was done, and after implementing inflow from the hepatic artery as well as backflow from the graft artery by embolectomy, re-anastomosis was conducted. In case of late presented HAT, interventional radiology and anticoagulation were done. In the case of HAS, a stent was inserted.

***Development and management of BCs***

Among the 169 RT-LDLT recipients included in this study, minor BLs occurred in 55 patients (32.5%) and stopped spontaneously without further management. Only in nine (16.4%) patients were pigtail insertion and further interventional management needed. Ninety-seven (57.4%) patients suffered from biliary infection; it mostly occurred early [91 (93.81%)], and 13 (7.7%) patients had three or more episodes (Table 1).

Sixty (35.5%) patients developed BS, most of which were anastomotic [59 (98.33%)], presented late [45 (75%)] and in one to two episodes [43 (25.4%)]. Most patients [45/60 (75%)] were HCV PCR positive during the occurrence of BS. Twenty-seven (45%) patients were not eligible for HCV antiviral treatment, while 14 (23.3%), 13 (21.7%) and 6 (10%) patients were treated before, during, and after the occurrence of BS, respectively (Table 1). Risk factors for BS were BL, biliary infection (especially if early or frequent), chronic graft rejection and longer graft arterialization time (Tables 3, 4 and Figure 2). In the multivariate analysis, graft arterialisation time > 130 min and biliary infection were the two determinants of BS (Table 5).

With respect to the management of BCs, ERCP with stenting ± dilatation was done for 60 (35.5%) patients, with 18 (10.7%) patients needing ≥ 3 ERCP sessions. PTC was attempted only in 8 (4.7%) patients, with one patient needing another session. These methods only failed in one patient who needed surgical reconstruction of BSs (Table 1).

***Chronic graft rejection***

Twenty-seven (16%) patients experienced chronic graft rejection. It was determined by biliary infection (especially if early or frequent), BS (especially if early or frequent), the need of ERCP (especially if multiple sessions), the number of stents used for BS treatment, hospital admission (especially if frequent) and recurrent HCV infection (Tables 1, 6 and Figure 3). The impact of these parameters on graft rejection was further demonstrated by multivariate analysis and Kaplan-Meier analysis (Table 7, Figure 4, and Supplementary material).

***Graft failure***

Graft failure developed in 20 (11.8%) patients; the causes were chronic graft rejection [6 (30%)], biliary infection [5 (25%)], recurrent HCV infection [3 (15%)], and other causes [6 (30%); Table 1]. BL, the need for pigtail catheter insertion, biliary infection (especially if frequent), recurrent HCV infection and non-response to HCV therapy were the risk factors of graft failure (Tables 8, 9 and Figure 5). Kaplan-Meier survival analysis further proved the impact of major BL and biliary infection on graft survival (Figure 6).

***Mortality***

A total of 28 (16.6%) deaths occurred during follow-up. The aetiologies of mortality were biliary infection [5 (17.9%)], chronic graft rejection [4 (14.3%)], recurrent HCV infection [3 (10.7%)], and other causes [16 (57.1%); Table 1]. Unresolved recurrent HCV infection was the only risk factor for mortality (Table 10 and Figure 7). This was further proved by Kaplan-Meier survival analysis (Figure 8).

**DISCUSSION**

LT is considered the only curative therapeutic option for patients with end-stage hepatic disease. Several complications, especially BC, still endanger its short and long-term outcomes[21,28,29]. Many studies have focused on BC to improve care for transplanted recipients; however, data on long-term outcomes remains scarce[28].

The BC incidence rate is extremely diverse between centres. The overall incidence of BC, including BL, biliary infection and BS, in our study was 57.4%. This rate is comparable to previous reports[17,30-33]; however, it is higher than other published data[8,15,21,34,35]. This difference can be attributed to the heterogeneous structure between the different studies regarding the type of graft, surgical techniques and the inconsistent inclusion of biliary infection and bile stones as a part of BC.

In addition to surgical techniques, several risk factors for BC have been defined in the published literature[3,7,14,21,36], such as older recipients and donors, female recipients and recipients of female donors, ABO mismatch, a prolonged anhepatic phase and prolonged ischemia times. However, the current study and other investigators[15,22,34] were unable to establish any of these conditions as risk factors for BC. This may be attributed to the inclusion of only ABO-matched living grafts, the younger age of our donors and recipients and the male predominance in our cohort.

Additionally, cholestatic liver diseases and the use of RYHJ technique were independent risk factors for BS in previous reports[15,37]. However, this is not the case in our study because DDA was used in all the grafts; besides, we excluded patients with PBC and PSC from the final analysis to avoid the bias of primary disease recurrence as a confounding factor during analysis of BC.

In accordance with published data[15,17], no association between BC and MELD score was observed. This result differs from studies recognizing a higher MELD score as a risk factor for BC[3,28,34]. This can be explained by the lower MELD scores in our patients. Also, these conflicting results may reflect the well-established limits of the MELD score in predicting post-LT outcomes[38].

The ideal material and style of sutures in biliary reconstruction has been argued since the early development of LT. Kaldas *et al*[17] reported that the use of non-absorbable sutures for biliary reconstruction was an independent risk factor for BC. However, this was not the case in the present study due to the different suture material.

In accordance with previous results[22], we observed that the occurrence of BS was not related to the number of bile ducts or stent insertion. In contrast, Miyagi *et al*[8] and Ogiso *et al*[34] identified the number of bile ducts as a risk factor for BC. Furthermore, Senter-Zapata *et al*[15] reported that internal biliary stents and T-tube insertion were risk factors for BC post-LT. However, in our centre, we prefer external drainage for easy accessibility of biliary ducts for postoperative cholangiography to manage any strictures[22]; on the contrary, other centres do not prefer this due to the higher incidence of postoperative BL and biliary infections[14].

BCs are mostly identified in the first three to 12 mo post-LT[8,17]. Similarly, in consistence with other reports[7,15,17,30,31,33], we detected BL early in 55/169 (32.5%) patients, and BS in 60/169 (35.5%) patients. The majority of BSs were anastomotic and presented late.

In a similar management plan as other centres[22,24,29,30,34], minor BLs were treated conservatively; nonetheless, major BL required percutaneous drainage and/or stenting. ERCP was the treatment of choice for all patients. PTC was the treatment option if ERCP failed, and surgical intervention was performed as a last option.

In consistence with our results, other investigators[7,8,21,39] observed that BL and cholangitis were risk factors for the development of BS. This can be explained by the inflammatory process with the resultant progression of fibrosis and stricture formation[40].

In agreement with Rammohan *et al*[39], we identified longer arterialization time as a risk factor for BS. This finding is predictable because biliary tract vascularization is supplied exclusively by the hepatic artery[41-43], and a longer arterialization time of the graft may cause biliary ischemia and subsequently BS[28].

In contrast to the present and Ogiso *et al*[34] studies, other investigators[15,17,28,29,41] reported that hepatic artery complications were linked to the incidence of BC. This conflicting result can be attributed to the low incidence of arterial complications in our cohort as well as the early effective intervention for such complications.

It was previously reported that graft rejection and BC are interrelated conditions[15,35]; however, there are limited data concerning the impact of BC on chronic graft rejection. The incidence rate of chronic ductopenic rejection in our study was 27 (16%) patients; 23 (85.18%),17 (63%) and 13 (48.1%) of them had biliary infection, BS and BL, respectively. Additionally, chronic graft rejection was a risk factor for BS.  Similar findings were reported by other investigators[44]. This is consistent with the histopathological findings of chronic ductopenic rejection where ductal inflammation and proliferation are seen in early stages and biliary duct fibrosis with progressive ductopenia is seen in late stages, which is manifested as intrahepatic BS by MRCP[45].

Biliary infection was a risk factor for chronic graft rejection and graft failure, which is explained by interrupted immunosuppressive therapy during times of sepsis[46,47].

In agreement with previous results[15,17,34,48], we found that the main reasons for graft failure were chronic ductopenic rejection, biliary infection, BL, and recurrent HCV infection, while Egeli *et al*[49] reported that HCC recurrence was the main cause of graft failure. This is justified by the inclusion of many patients beyond Milan criteria in their study.

In contrast to Mathur *et al*[50] and in consistence with other investigators[8,17,34,41], there was no association between BS and graft failure. This proves that early detection and efficient management of BS can prevent graft loss.

In the current study, recurrent HCV infection was a risk factor for chronic graft rejection, graft failure and mortality. This is predictable due to the aggressive course of HCV recurrence in LT recipients through direct cytotoxic effects on the graft, resulting in graft failure[48,49,51-53]. It is noteworthy that DAA were not FDA approved during the first three years of the study duration; thus, many patients were ineligible for the Peg-IFN/RBV regimen at that time.

Similar to Takagi *et al*[54] study, the overall mortality rate for recipients was 28 (16.56%). Unresolved HCV recurrence was the only significant risk factor for mortality, while BC had no impact on recipients’ survival in the present study. This is similar to previous results[17,21,39,41,49]. In contrast, other investigators[15,33] observed a worse survival rate in recipients with BC. This indicates that early detection and effective management of BC can improve recipients’ survival[2,17].

This study has the strength of being large volume with a long duration of follow-up, as well as the exclusion of LDLT recipients because of cholestatic hepatic diseases; however, it is limited by being a single-centre retrospective study. Multi-centre large-scale studies are required to comprehensively investigate the risk factors for the occurrence and impacts of BC.

**CONCLUSION**

In conclusion, biliary complications after RT-LDLT represent an independent risk factor for chronic graft rejection and graft failure; nonetheless, effective management of these complications can improve patient and graft survival.

**ARTICLE HIGHLIGHTS**

***Research background***

Despite considerable progress in liver transplantation (LT) surgical performance and peri-operative management, post-LT biliary complications (BCs) remain a considerable cause of morbidity, mortality, increased cost, and graft loss.

***Research motivation***

Many studies have focused on biliary complications to improve care for transplanted recipients; however, data on long-term outcomes remain scarce.

***Research objectives***

We aimed to investigate the impact of BCs after right lobe-LDLT (RL-LDLT) on chronic graft rejection, graft failure and mortality.

***Research methods***

From 2011 to 2016, 215 adult recipients underwent RL-LDLT at our centre. We excluded 46 recipients who met the exclusion criteria, and 169 recipients were included in the final analysis. Donors’ and recipients’ demographic data, clinical data, operative details and postoperative course information were collected. We also reviewed the management and outcomes of BCs. Recipients were followed for at least 12 mo post-LT until December 2017 or graft or patient loss.

***Research results***

The overall incidence rate of BCs including biliary leakage, biliary infection and biliary stricture was 57.4%. Twenty-seven (16%) patients experienced chronic graft rejection. Graft failure developed in 20 (11.8%) patients. A total of 28 (16.6%) deaths occurred during follow-up. BCs were a risk factor for the occurrence of chronic graft rejection and failure; however, mortality was determined by recurrent hepatitis C virus infection.

***Research conclusions***

Biliary complications after RT-LDLT represent an independent risk factor for chronic graft rejection and graft failure; nonetheless, effective management of these complications can improve patient and graft survival.

***Research perspectives***

Multi-centre large-scale studies are required to comprehensively investigate the risk factors for the occurrence and impacts of BC.

**REFERENCES**

1 **Jadlowiec CC**, Taner T. Liver transplantation: Current status and challenges. *World J Gastroenterol* 2016; **22**: 4438-4445 [PMID: 27182155 DOI: 10.3748/wjg.v22.i18.4438]

2 **Chang JH**, Lee I, Choi MG, Han SW. Current diagnosis and treatment of benign biliary strictures after living donor liver transplantation. *World J Gastroenterol* 2016; **22**: 1593-1606 [PMID: 26819525 DOI: 10.3748/wjg.v22.i4.1593]

3 **Nemes B**, Gámán G, Doros A. Biliary complications after liver transplantation. *Expert Rev Gastroenterol Hepatol* 2015; **9**: 447-466 [PMID: 25331256 DOI: 10.1586/17474124.2015.967761]

4 **Tsujino T**, Isayama H, Kogure H, Sato T, Nakai Y, Koike K. Endoscopic management of biliary strictures after living donor liver transplantation. *Clin J Gastroenterol* 2017; **10**: 297-311 [PMID: 28600688 DOI: 10.1007/s12328-017-0754-z]

5 **Rela M**, Reddy MS. Living donor liver transplant (LDLT) is the way forward in Asia. *Hepatol Int* 2017; **11**: 148-151 [PMID: 28097531 DOI: 10.1007/s12072-016-9780-z]

6 **Doyle MB**, Maynard E, Lin Y, Vachharajani N, Shenoy S, Anderson C, Earl M, Lowell JA, Chapman WC. Outcomes with split liver transplantation are equivalent to those with whole organ transplantation. *J Am Coll Surg* 2013; **217**: 102-12; discussion 113-4 [PMID: 23639200 DOI: 10.1016/j.jamcollsurg.2013.03.003]

7 **Rao HB**, Prakash A, Sudhindran S, Venu RP. Biliary strictures complicating living donor liver transplantation: Problems, novel insights and solutions. *World J Gastroenterol* 2018; **24**: 2061-2072 [PMID: 29785075 DOI: 10.3748/wjg.v24.i19.2061]

8 **Miyagi S**, Kakizaki Y, Shimizu K, Miyazawa K, Nakanishi W, Hara Y, Tokodai K, Nakanishi C, Kamei T, Ohuchi N, Satomi S. Arterial and biliary complications after living donor liver transplantation: a single-center retrospective study and literature review. *Surg Today* 2018; **48**: 131-139 [PMID: 28439714 DOI: 10.1007/s00595-017-1515-9]

9 **Baker TB**, Zimmerman MA, Goodrich NP, Samstein B, Pomfret EA, Pomposelli JJ, Gillespie BW, Berg CL, Emond JC, Merion RM. Biliary reconstructive techniques and associated anatomic variants in adult living donor liver transplantations: The adult-to-adult living donor liver transplantation cohort study experience. *Liver Transpl* 2017; **23**: 1519-1530 [PMID: 28926171 DOI: 10.1002/lt.24872]

10 **Lee SG**. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. *Am J Transplant* 2015; **15**: 17-38 [PMID: 25358749 DOI: 10.1111/ajt.12907]

11 **Chok KS**, Lo CM. Prevention and management of biliary anastomotic stricture in right-lobe living-donor liver transplantation. *J Gastroenterol Hepatol* 2014; **29**: 1756-1763 [PMID: 24909190 DOI: 10.1111/jgh.12648]

12 **Samstein B**, Smith AR, Freise CE, Zimmerman MA, Baker T, Olthoff KM, Fisher RA, Merion RM. Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study. *Am J Transplant* 2016; **16**: 594-602 [PMID: 26461803 DOI: 10.1111/ajt.13479]

13 **Simoes P**, Kesar V, Ahmad J. Spectrum of biliary complications following live donor liver transplantation. *World J Hepatol* 2015; **7**: 1856-1865 [PMID: 26207167 DOI: 10.4254/wjh.v7.i14.1856]

14 **Girometti R**, Pancot M, Como G, Zuiani C. Imaging of liver transplantation. *Eur J Radiol* 2017; **93**: 295-307 [PMID: 28545872 DOI: 10.1016/j.ejrad.2017.05.014]

15 **Senter-Zapata M**, Khan AS, Subramanian T, Vachharajani N, Dageforde LA, Wellen JR, Shenoy S, Majella Doyle MB, Chapman WC. Patient and Graft Survival: Biliary Complications after Liver Transplantation. *J Am Coll Surg* 2018; **226**: 484-494 [PMID: 29360615 DOI: 10.1016/j.jamcollsurg.2017.12.039]

16 **Oh HC**. Percutaneous Transhepatic Cholangioscopy in Bilioenteric Anastomosis Stricture. *Clin Endosc* 2016; **49**: 530-532 [PMID: 27642850 DOI: 10.5946/ce.2016.125]

17 **Kaldas FM**, Korayem IM, Russell TA, Agopian VG, Aziz A, DiNorcia J, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW. Assessment of Anastomotic Biliary Complications in Adult Patients Undergoing High-Acuity Liver Transplant. *JAMA Surg* 2019; **154**: 431-439 [PMID: 30758485 DOI: 10.1001/jamasurg.2018.5527]

18 **Lee DW**, Jo HH, Abdullah J, Kahaleh M. Endoscopic Management of Anastomotic Strictures after Liver Transplantation. *Clin Endosc* 2016; **49**: 457-461 [PMID: 27744664 DOI: 10.5946/ce.2016.130]

19 **Koo PT**, Medici V, Tabibian JH. Anastomotic Biliary Stricture Development after Liver Transplantation in the Setting of Retained Prophylactic Intraductal Pediatric Feeding Tube: Case and Review. *Case Reports Hepatol* 2018; **2018**: 4707389 [PMID: 30363933 DOI: 10.1155/2018/4707389]

20 **Crismale JF**, Ahmad J. Endoscopic Management of Biliary Issues in the Liver Transplant Patient. *Gastrointest Endosc Clin N Am* 2019; **29**: 237-256 [PMID: 30846151 DOI: 10.1016/j.giec.2018.11.003]

21 **Hong SY**, Hu XG, Lee HY, Won JH, Kim JW, Shen XY, Wang HJ, Kim BW. Longterm Analysis of Biliary Complications After Duct-to-Duct Biliary Reconstruction in Living Donor Liver Transplantations. *Liver Transpl* 2018; **24**: 1050-1061 [PMID: 29633539 DOI: 10.1002/lt.25074]

22 **Azzam AZ**, Tanaka K. Biliary complications after living donor liver transplantation: A retrospective analysis of the Kyoto experience 1999-2004. *Indian J Gastroenterol* 2017; **36**: 296-304 [PMID: 28744748 DOI: 10.1007/s12664-017-0771-3]

23 **Santosh Kumar KY**, Mathew JS, Balakrishnan D, Bharathan VK, Thankamony Amma BSP, Gopalakrishnan U, Narayana Menon R, Dhar P, Vayoth SO, Sudhindran S. Intraductal Transanastomotic Stenting in Duct-to-Duct Biliary Reconstruction after Living-Donor Liver Transplantation: A Randomized Trial. *J Am Coll Surg* 2017; **225**: 747-754 [PMID: 28916322 DOI: 10.1016/j.jamcollsurg.2017.08.024]

24 **Elwir S**, Thompson J, Amateau SK, Trikudanathan G, Attam R, Hassan M, Kandaswamy R, Pruett T, Lake J, Chinnakotla S, Freeman ML, Arain MA. Endoscopic Management of Biliary Leaks and Strictures After Living Donor Liver Transplantation: Optimizing Techniques for Successful Management. *Dig Dis Sci* 2017; **62**: 244-252 [PMID: 27866300 DOI: 10.1007/s10620-016-4367-z]

25 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

26 **Ishiko T**, Egawa H, Kasahara M, Nakamura T, Oike F, Kaihara S, Kiuchi T, Uemoto S, Inomata Y, Tanaka K. Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe graft. *Ann Surg* 2002; **236**: 235-240 [PMID: 12170029 DOI: 10.1097/00000658-200208000-00012]

27 **Tanaka K**, Uemoto S, Tokunaga Y, Fujita S, Sano K, Nishizawa T, Sawada H, Shirahase I, Kim HJ, Yamaoka Y. Surgical techniques and innovations in living related liver transplantation. *Ann Surg* 1993; **217**: 82-91 [PMID: 8424706 DOI: 10.1097/00000658-199301000-00014]

28 **Kaltenborn A**, Gutcke A, Gwiasda J, Klempnauer J, Schrem H. Biliary complications following liver transplantation: Single-center experience over three decades and recent risk factors. *World J Hepatol* 2017; **9**: 147-154 [PMID: 28217251 DOI: 10.4254/wjh.v9.i3.147]

29 **Coelho JCU**, Leite LO, Molena A, Freitas ACT, Matias JEF. BILIARY COMPLICATIONS AFTER LIVER TRANSPLANTATION. *Arq Bras Cir Dig* 2017; **30**: 127-131 [PMID: 29257849 DOI: 10.1590/0102-6720201700020011]

30 **Rao HB**, Koshy AK, Sudhindran S, Prabhu NK, Venu RP. Paradigm shift in the management of bile duct strictures complicating living donor liver transplantation. *Indian J Gastroenterol* 2019; **38**: 488-497 [PMID: 32065353 DOI: 10.1007/s12664-019-01000-2]

31 **Iesari S**, Inostroza Núñez ME, Rico Juri JM, Ciccarelli O, Bonaccorsi-Riani E, Coubeau L, Laterre PF, Goffette P, De Reyck C, Lengelé B, Gianello P, Lerut J. Adult-to-adult living-donor liver transplantation: The experience of the Université catholique de Louvain. *Hepatobiliary Pancreat Dis Int* 2019; **18**: 132-142 [PMID: 30850341 DOI: 10.1016/j.hbpd.2019.02.007]

32 **Boraschi P**, Donati F, Pacciardi F, Ghinolfi D, Falaschi F. Biliary complications after liver transplantation: Assessment with MR cholangiopancreatography and MR imaging at 3T device. *Eur J Radiol* 2018; **106**: 46-55 [PMID: 30150050 DOI: 10.1016/j.ejrad.2018.07.009]

33 **Hafeez Bhatti AB**, Dar FS, Qureshi AI, Khan NY, Zia HH, Khan EUD, Khan NA, Salih M, Shah NH. Failure to rescue in living donor liver transplantation: Patterns and predictors. *Int J Surg* 2017; **44**: 281-286 [PMID: 28694002 DOI: 10.1016/j.ijsu.2017.07.026]

34 **Ogiso S**, Kamei H, Onishi Y, Kurata N, Jobara K, Kawashima H, Ogura Y. Decreased long-term graft survival in persistent biliary complications after right-lobe living-donor liver transplantation. *Clin Transplant* 2020; **34**: e13771 [PMID: 31846118 DOI: 10.1111/ctr.13771]

35 **Dogan N**, Hüsing-Kabar A, Schmidt HH, Cicinnati VR, Beckebaum S, Kabar I. Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure. *J Int Med Res* 2018; **46**: 3979-3990 [PMID: 29996675 DOI: 10.1177/0300060518785543]

36 **Memeo R**, Piardi T, Sangiuolo F, Sommacale D, Pessaux P. Management of biliary complications after liver transplantation. *World J Hepatol* 2015; **7**: 2890-2895 [PMID: 26689137 DOI: 10.4254/wjh.v7.i29.2890]

37 **Pena Polanco NA**, Levy C, Martin EF. Cholestatic Liver Diseases After Liver Transplant. *Clin Liver Dis* 2017; **21**: 403-420 [PMID: 28364821 DOI: 10.1016/j.cld.2016.12.011]

38 **Rana A**, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, Guarrera JV, Brown RS Jr, Emond JC. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. *Am J Transplant* 2008; **8**: 2537-2546 [PMID: 18945283 DOI: 10.1111/j.1600-6143.2008.02400.x]

39 **Rammohan A**, Govil S, Vargese J, Kota V, Reddy MS, Rela M. Changing pattern of biliary complications in an evolving liver transplant unit. *Liver Transpl* 2017; **23**: 478-486 [PMID: 28152569 DOI: 10.1002/lt.24736]

40 **Daniel K**, Said A. Early Biliary complications after liver transplantation. *Clin Liver Dis (Hoboken)* 2017; **10**: 63-67 [PMID: 30992762 DOI: 10.1002/cld.654]

41 **Jeong S**, Wang X, Wan P, Sha M, Zhang J, Xia L, Tong Y, Luo Y, Xia Q. Risk factors and survival outcomes of biliary complications after adult-to-adult living donor liver transplantation. *United European Gastroenterol J* 2017; **5**: 997-1006 [PMID: 29163966 DOI: 10.1177/2050640616688994]

42 **Kim PT**, Fernandez H, Gupta A, Saracino G, Ramsay M, McKenna GJ, Testa G, Anthony T, Onaca N, Ruiz RM, Klintmalm GB. Low Measured Hepatic Artery Flow Increases Rate of Biliary Strictures in Deceased Donor Liver Transplantation: An Age-Dependent Phenomenon. *Transplantation* 2017; **101**: 332-340 [PMID: 27941438 DOI: 10.1097/TP.0000000000001564]

43 **Nacif LS,** Ducatti L, Andraus W, D’Albuquerque LC. Hepatic Artery Thrombosis after Orthotopic Liver Transplantation. *Adv Res Gastroentero Hepatol* 2015; **1**: 555560 [DOI: 10.19080/ARGH.2015.01.555560]

44 **Mocchegiani F**, Vincenzi P, Lanari J, Montalti R, Nicolini D, Svegliati Baroni G, Risaliti A, Vivarelli M. Immunological risk factors in biliary strictures after liver transplantation. *Ann Transplant* 2015; **20**: 218-224 [PMID: 25892243 DOI: 10.12659/AOT.892393]

45 **Koukoulis GK**, Shen J, Karademir S, Jensen D, Williams J. Cholangiocytic apoptosis in chronic ductopenic rejection. *Hum Pathol* 2001; **32**: 823-827 [PMID: 11521226 DOI: 10.1053/hupa.2001.26465]

46 **Tannuri AC**, Lima F, Mello ES, Tanigawa RY, Tannuri U. Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation. *Clinics (Sao Paulo)* 2016; **71**: 216-220 [PMID: 27166772 DOI: 10.6061/clinics/2016(04)07]

47 **Horster S**, Bäuerlein FJ, Mandel P, Raziorrouh B, Hopf C, Stemmler HJ, Guba M, Angele M, Stangl M, Rentsch M, Frey L, Kaspar M, Kaczmarek I, Eberle J, Nickel T, Gruener N, Zachoval R, Diepolder H. Influence of hepatitis C virus infection and high virus serum load on biliary complications in liver transplantation. *Transpl Infect Dis* 2013; **15**: 306-313 [PMID: 23489913 DOI: 10.1111/tid.12069]

48 **Huesing-Kabar A**, Dohna CZ, Heinzow H, Cicinnati VR, Beckebaum S, Schmidt M, Gerth HU, Pohlen M, Wilms C, Palmes D, Schmidt HH, Kabar I. Risk factors for allograft failure in liver transplant recipients. *Z Gastroenterol* 2018; **56**: 745-751 [PMID: 29341040 DOI: 10.1055/s-0043-125225]

49 **Egeli T**, Unek T, Ağalar C, Derici S, Ozbilgin M, Akarasu M, Bacakoglu A, Ellidokuz H, Astarcıoglu I. Analysis of Causes and Risk Factors for Late Mortality After Liver Transplant: How Can We Obtain Better Long-Term Survival? *Exp Clin Transplant* 2020; **18**: 182-187 [PMID: 29863452 DOI: 10.6002/ect.2017.0346]

50 **Mathur AK**, Nadig SN, Kingman S, Lee D, Kinkade K, Sonnenday CJ, Welling TH. Internal biliary stenting during orthotopic liver transplantation: anastomotic complications, post-transplant biliary interventions, and survival. *Clin Transplant* 2015; **29**: 327-335 [PMID: 25604635 DOI: 10.1111/ctr.12518]

51 **Berge E**, Otón E, Reina Z, Díaz L, Márquez A, Cejas L, Acosta S, Pérez F. Predictors of Poor Prognosis in Recurrent Hepatitis C After Liver Transplantation. *Transplant Proc* 2016; **48**: 2997-2999 [PMID: 27932129 DOI: 10.1016/j.transproceed.2016.07.043]

52 **Shiba H**, Hashimoto K, Kelly D, Fujiki M, Quintini C, Aucejo F, Uso TD, Yerian L, Yanaga K, Matsushima M, Eghtesad B, Fung J, Miller C. Risk stratification of allograft failure secondary to hepatitis C recurrence after liver transplantation. *Hepatol Res* 2016; **46**: 1099-1106 [PMID: 26833562 DOI: 10.1111/hepr.12661]

53 **Llovet LP**, Sciarrone S, Rodríguez-Tajes S, Montironi C, Mescoli C, Rugge M, Crespo G, Burra P, Forns X, Diaz A, Londoño MC. Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. *Gastroenterol Hepatol* 2020; **43**: 14-21 [PMID: 31495536 DOI: 10.1016/j.gastrohep.2019.07.006]

54 **Takagi K**, Domagala P, Polak WG, Ijzermans JNM, Boehnert MU. Right posterior segment graft for living donor liver transplantation: A systematic review. *Transplant Rev (Orlando)* 2020; **34**: 100510 [PMID: 31495539 DOI: 10.1016/j.trre.2019.100510]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the institutional review board of Faculty of Medicine, Ain Shams University, Cairo, Egypt.

**Informed consent statement:** Informed consent statement was waived due to the retrospective nature of the study.

**Conflict-of-interest statement:** All authors have nothing to disclose.

**Data sharing statement:** The statistical code and dataset are available from the corresponding author at ghadaabdelrahman@med.asu.edu.eg

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 9, 2021

**First decision:** May 2, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Egypt

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** lee Y, Ou HY, zhang W **S-Editor:** Wu YXJ **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Flow chart of study cohort.** LT: Liver transplantation; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis.



**Figure 2 Forest plot for risk factors for biliary strictures.** HCV: Hepatitis C virus.



**Figure 3 Incidence of chronic graft rejection according to the occurrence of biliary strictures (A) and biliary infections (B).**





**Figure 4 Kaplan-Meier curves.** A-C: The curves showing the probability of chronic graft rejection in patients regarding the occurrence (A), timing (B), and frequency (C) of biliary infection; D-F: The curves showing the probability of chronic graft rejection in patients regarding the occurrence (D), timing (E), and frequency (F) of biliary strictures.



**Figure 5 Incidence of graft failure according to the occurrence of biliary infections (A) and biliary leakage (B).**



**Figure 6 Kaplan-Meier curves.** The curves showing the probability of graft failure in patients regarding the occurrence of biliary infection (A) and large bile leaks as indicated by pigtail insertion (B).



**Figure 7 Mortality rate in patients with or without resolution of recurrent hepatitis C virus in patient with biliary stricture.** HCV: Hepatitis C virus.



**Figure 8 Kaplan-Meier curves showing the survival probability of patients with resolved or unresolved hepatitis C virus.** HCV: Hepatitis C virus.

**Table 1 Descriptive categorical data for the whole study population**

|  |  |  |
| --- | --- | --- |
| **Variable** |  | ***n*** (%**)** |
| Etiology of cirrhosis | HCV | 148 (87.6) |
| HBV | 5 (3) |
| Combined HCV & HBV | 4 (2.4) |
| Others | 12 (7.1) |
| Hepatocellular carcinoma | - | 109 (64.5) |
| + | 60 (35.5) |
| Donors’ gender | Male | 141 (83.4) |
| Female | 28 (16.6) |
| Recipients’ gender | Male | 150 (88.8) |
| Female | 19 (11.2) |
| HCV PCR viremia prior to transplantation | Negative | 33 (19.52) |
| Below 200 000 IU | 59 (34.91) |
| 200000 to 2 million | 69 (40.82) |
| More than 2 million | 8 (4.73) |
| Antiviral treatment for HCV prior to transplantation | - | 138 (81.7) |
| + | 31 (18.3) |
| Arterial complications | - | 155 (91.7) |
| + | 14 (8.3) |
| Number of anastomosis | 1 Anastomosis | 109 (64.5) |
| 2 Anastomosis | 57 (33.7) |
| 3 Anastomosis | 3 (1.8) |
| Number of ducts | 1 Duct | 78 (46.2) |
| 2 Ducts | 78 (46.2) |
| 3 Ducts | 12 (7.1) |
| 4 Ducts | 1 (0.6) |
| Number of stents introduced at surgery | Nil | 7 (4.1) |
| 1 Stent | 71 (42) |
| 2 Stents | 79 (46.7) |
| 3 Stents | 11 (6.5) |
| 4 Stents | 1 (0.6) |
| Immunosuppressant | Tacrolimus  | 118 (69.8) |
| Cyclosporine | 51 (30.2) |
| Biliary leakage | - | 114 (67.5) |
| + | 55 (32.5) |
| Need of pigtail catheter for biloma | - | 46 (83.6) |
| + | 9 (16.4) |
| Biliary infection  | - | 72 (42.6) |
| + | 97 (57.4) |
| Frequency of biliary infection | 1-2 Episodes | 84 (49.7) |
| ≥ 3 Episodes | 13 (7.7) |
| Biliary stricture | - | 109 (64.5) |
| + | 60 (35.5) |
| Frequency of biliary stricture | 1-2 Episodes | 43 (25.4) |
| ≥ 3 Episodes | 17 (10.1) |
| Need for ERCP | - | 109 (64.5) |
| + | 60 (35.5) |
| Frequency of ERCP | 1-2 ERCP | 42 (24.9) |
| ≥ 3 ERCP | 18 (10.7) |
| Need for PTC | - | 161 (95.3) |
| + | 8 (4.7) |
| Frequency of PTC | 1 PTC | 7 (4.1) |
| 2 PTC | 1 (0.6) |
| Surgical intervention for stricture | - | 168 (99.4) |
| + | 1 (0.6) |
| HCV PCR during occurrence of stricture | Negative | 15 (25) |
| Below 200 000 IU | 15 (25) |
| 200000 to 2 million | 19 (31.7) |
| More than 2 million | 11 (18.3) |
| HCV antiviral treatment in relation to stricture diagnosis | No treatment | 27 (45) |
| Before stricture | 14 (23.3) |
| During occurrence of stricture | 13 (21.7) |
| After stricture | 6 (10) |
| Admission related to BC | - | 95 (56.2) |
| + | 74 (43.8) |
| Mortality | - | 141 (83.4) |
| + | 28 (16.6) |
| Cause of mortality (total number: 28) | Biliary sepsis | 5 (17.9) |
| Graft rejection | 4 (14.3) |
| Recurrent HCV | 3 (10.7) |
| Other causes | 16 (57.1) |
| Chronic rejection | - | 142 (84) |
| + | 27 (16) |
| Recurrent HCV infection | - | 128 (75.7) |
| + | 41 (24.3) |
| Resolution of recurrent HCV | - | 4 (9.8) |
| + | 37 (90.2) |
| Graft failure | - | 149 (88.2) |
| + | 20 (11.8) |
| Causes of graft failure (total number: 20) | Biliary sepsis | 5 (25) |
| Graft rejection | 6 (30) |
| Recurrent HCV | 3 (15) |
| Other causes | 6 (30) |
| Early biliary infection (total = 97) | - | 6 (6.18) |
| + | 91 (93.81) |
| Early biliary stricture (total = 60) | - | 45 (75) |
| + | 15 (25) |

Data presented in number (*n*) and percentage (%). HCV: Hepatitis C virus; HBV: Hepatitis B virus; PCR: Polymerase chain reaction; ERCP: Endoscopic retrograde cholangiopancreatography; PTC: Percutaneous transhepatic cholangiography; BC: Biliary complication.

**Table 2 Descriptive numerical data for the whole study population**

|  |  |
| --- | --- |
| **Variable**  | **Data** |
| MELD score | 16 ± 4 |
| Child score | 10 ± 2 |
| Donors’ age (yr) | 27 ± 6 |
| Donors’ BMI (kg/m2) | 24 ± 3 |
| Recipient's age (yr) | 50 ± 8 |
| Recipient's BMI (kg/m2) | 28 ± 4 |
| Total bilirubin (mg/dL) | 2.6 (1.9-3.8) |
| Direct bilirubin (mg/dL) | 1.3 (0.7-2.1) |
| Alkaline phosphatase (IU/L) | 104 ± 48 |
| Gamma-glutamyl transferase (IU/L) | 36 (19-61) |
| Platelets (109/L) | 79 ± 35 |
| Cold ischemia time (min) | 49 ± 24 |
| Warm ischemia time (min) | 48 ± 20 |
| Graft arterialization time (min) | 141 ± 51 |
| Time to biliary infection (d) | 16 (11-30) |
| Time to biliary stricture (d) | 150 (120-218) |
| Time to mortality (d) | 285 (55-808) |
| Time to chronic graft rejection (d) | 490 (230-920) |
| Time to recurrent HCV (d) | 391 (180-714) |
| Time to graft failure (d) | 556 (135-1267) |

Data are presented as mean ± SD or median and range. MELD: Model for end-stage liver disease; BMI: Body mass index; HCV: Hepatitis C virus.

**Table 3 Risk factors for biliary strictures: Categorical factors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Biliary strictures** | **OR** | **CI** | ***P* value1** |
| **No stricture (*n* = 109)** | **Stricture (*n* = 60)** | **95% LCL** | **95% UCL** |
| ***n,* Row %** | ***n,* Row %** |
| Etiology of cirrhosis | HCV | 95 (64.2) | 53 (35.8) |  |  |  | 0.1422 |
| Isolated HBV | 5 (100) | 0 (0) |
| Combined HCV & HBV | 1 (25) | 3 (75) |
| Causes other than viral hepatitis | 8 (66.7) | 4 (33.3) |
| Donors’ gender | Male | 90 (63.8) | 51 (36.2) | 0.8 | 0.4 | 2.0 | 0.684 |
| Female | 19 (67.9) | 9 (32.1) |
| Recipients’ gender | Male | 96 (64) | 54 (36) | 0.8 | 0.3 | 2.3 | 0.704 |
| Female | 13 (68.4) | 6 (31.6) |
| HCV PCR viremia prior to transplantation | Negative | 20 (60.6) | 13 (39.4) |  |  |  | 0.7683 |
| Below 200000 IU | 41 (69.5) | 18 (30.5) |
| 200000 to 2 million | 44 (63.8) | 25 (36.2) |
| More than 2 million | 4 (50) | 4 (50) |
| Antiviral treatment prior to transplantation | - | 92 (66.7) | 46 (33.3) | 1.6 | 0.7 | 3.6 | 0.214 |
| + | 17 (54.8) | 14 (45.2) |
| Hepatocellular carcinoma | - | 71 (65.1) | 38 (34.9) | 1.1 | 0.6 | 2.1 | 0.815 |
| + | 38 (63.3) | 22 (36.7) |
| Arterial complications | - | 102 (65.8) | 53 (34.2) | 1.9 | 0.6 | 5.8 | 0.2552 |
| + | 7 (50) | 7 (50) |
| Number of anastomoses | One  | 70 (64.2) | 39 (35.8) |  |  |  | 0.9103 |
| Two  | 37 (64.9) | 20 (35.1) |
| Three | 2 (66.7) | 1 (33.3) |
| Number of ducts | 1 Duct | 50 (64.1) | 28 (35.9) |  |  |  | 0.8573 |
| 2 Ducts | 52 (66.7) | 26 (33.3) |
| 3 Ducts | 6 (50) | 6 (50) |
| 4 Ducts | 1 (100) | 0 (0) |
| Number of stents | Nil | 5 (71.4) | 2 (28.6) |  |  |  | 0.5783 |
| 1 Stent | 43 (60.6) | 28 (39.4) |
| 2 Stents | 53 (67.1) | 26 (32.9) |
| 3 Stents | 7 (63.6) | 4 (36.4) |
| 4 Stents | 1 (100) | 0 (0) |
| Immunosuppressant | Tacrolimus | 81 (68.6) | 37 (31.4) | 1.8 | 0.9 | 3.5 | 0.087 |
| Cyclosporine  | 28 (54.9) | 23 (45.1) |
| Biliary leakage | - | 80 (70.2) | 34 (29.8) | 2.1 | 1.1 | 4.1 | **0.026** |
| + | 29 (52.7) | 26 (47.3) |
| Biliary infection | - | 62 (86.1) | 10 (13.9) | 6.6 | 3.0 | 14.4 | **< 0.001** |
| + | 47 (48.5) | 50 (51.5) |
| Frequency of biliary infection | Nil | 62 (86.1) | 10 (13.9) |  |  |  | **< 0.0013** |
| 1-2 Episodes | 45 (53.6) | 39 (46.4) |
| ≥ 3 Episodes | 2 (15.4) | 11 (84.6) |
| Early biliary infection | - | 64 (82.1) | 14 (17.9) | 4.7 | 2.3 | 9.5 | **< 0.001** |
| + | 45 (49.5) | 46 (50.5) |
| Chronic graft rejection | - | 99 (69.7) | 43 (30.3) | 3.9 | 1.7 | 9.2 | **0.001** |
| + | 10 (37) | 17 (63) |
| Recurrent HCV | - | 87 (68) | 41 (32) | 1.8 | 0.9 | 3.8 | 0.096 |
| + | 22 (53.7) | 19 (46.3) |

1Pearson chi-squared test unless otherwise indicated.

2Fisher’s exact test.

3Chi-squared test for trend.

Data are presented as number (*n*) and percentage (%). OR: Odds ratio; LCL: Lower confidence limit; UCL: Lower confidence limit. HCV: Hepatitis C virus; HBV: Hepatitis B virus; PCR: Polymerase chain reaction.

**Table 4 Risk factors for biliary stricture: Numerical factors**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **No biliary stricture (*n* = 109)** | **Biliary stricture (*n* = 60)** | ***P* value1** |
| MELD score | 15 (13-18) | 15 (13-19) | 0.588 |
| CHILD score | 10 (9-11) | 9 (8-11) | 0.198 |
| Donors’ age (yr) | 27 (23-30) | 25 (24-30) | 0.727 |
| Donors’ BMI (kg/m2) | 25 (23-26) | 24 (22-26) | 0.155 |
| Recipient's age (yr) | 51 (46-56) | 52 (48-55) | 0.961 |
| Recipient's BMI (kg/m2) | 27 (25-30) | 27 (26-30) | 0.219 |
| Total bilirubin (mg/dL) | 2.6 (1.9-3.7) | 2.5 (1.9-4.1) | 0.911 |
| Direct bilirubin (mg/dL) | 1.3 (0.8-2.1) | 1.3 (0.7-1.9) | 0.405 |
| Alkaline phosphatase (IU/L) | 99 (70-118) | 84 (68-143) | 0.982 |
| GGT (IU/L) | 36 (19-63) | 34 (22-60) | 0.992 |
| Platelets (109/L) | 70 (51-104) | 68 (51-102) | 0.830 |
| Cold ischemia time (min) | 45 (30-60) | 45 (30-60) | 0.929 |
| Warm ischemia time (min) | 45 (35-60) | 45 (35-60) | 0.860 |
| Graft arterialization time (min) | 120 (90-150) | 155 (120-205) | **< 0.001** |

1Mann-Whitney U test.

Data are presented as median and interquartile range (IQR). MELD: Model for end-stage liver disease; BMI: Body mass index.

**Table 5 Multivariable binary logistic regression model for prediction of biliary stricture**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | ***P* value** | **Odds ratio** | **95%CI** |
| Graft arterializations time > 130 min | **0.001** | 3.705 | 1.669-8.224 |
| Biliary leakage | 0.649 | 1.208 | 0.536-2.726 |
| > 1 Episode of biliary infection | **< 0.0001** | 9.892 | 4.086-23.952 |
| Chronic graft rejection | 0.173 | 2.088 | 0.725-6.014 |

CI: Confidence interval.

**Table 6 Relation between biliary complications and chronic graft rejection**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **No Chronic graft rejection (*n* = 142), *n* (%)** | **Chronic graft rejection (*n* = 27), *n* (%)** | **OR** | **CI** | ***P* value1** |
| **95% LCL** | **95% UCL** |
| Biliary leakage | - | 100 (87.7) | 14 (12.3) | 2.2 | 1.0 | 5.1 | 0.059 |
| + | 42 (76.4) | 13 (23.6) |
| Insertion of pigtail catheter for biliary leakage | - | 135 (84.4) | 25 (15.6) | 1.5 | 0.3 | 7.9 | 0.6372 |
| + | 7 (77.8) | 2 (22.2) |
| Biliary infection | - | 68 (94.4) | 4 (5.6) | 5.3 | 1.7 | 16.1 | **0.001** |
| + | 74 (76.3) | 23 (23.7) |
| Frequency of biliary infection | Nil | 68 (94.4) | 4 (5.6) |  |  |  | **< 0.0013** |
| 1-2 Episodes | 68 (81) | 16 (19) |
| ≥ 3 Episodes | 6 (46.2) | 7 (53.8) |
| Early biliary infection | - | 73 (93.6) | 5 (6.4) | 4.7 | 1.7 | 13.0 | **0.002** |
| + | 69 (75.8) | 22 (24.2) |
| Biliary stricture | - | 99 (90.8) | 10 (9.2) | 3.9 | 1.7 | 9.2 | **0.001** |
| + | 43 (71.7) | 17 (28.3) |
| Frequency of biliary strictures | Nil | 99 (90.8) | 10 (9.2) |  |  |  | **0.0013** |
| 1-2 Episodes | 32 (74.4) | 11 (25.6) |
| ≥ 3 Episodes | 11 (64.7) | 6 (35.3) |
| Early biliary stricture | - | 134 (87) | 20 (13) | 5.9 | 1.9 | 17.9 | **0.0032** |
| + | 8 (53.3) | 7 (46.7) |
| Need for ERCP | - | 99 (90.8) | 10 (9.2) | 3.9 | 1.7 | 9.2 | **0.001** |
| + | 43 (71.7) | 17 (28.3) |
| Frequency of ERCP | Nil | 99 (90.8) | 10 (9.2) |  |  |  | **0.0013** |
| 1-2 ERCP | 31 (73.8) | 11 (26.2) |
| ≥ 3 ERCP | 12 (66.7) | 6 (33.3) |
| Number of stents introduced for stricture | Nil | 102 (91.1) | 10 (8.9) |  |  |  | **0.0023** |
| 1-2 stents | 25 (73.5) | 9 (26.5) |
| ≥ 3 stents | 15 (65.2) | 8 (34.8) |
| Need for PTC | - | 136 (84.5) | 25 (15.5) | 1.8 | 0.3 | 9.5 | 0.6152 |
| + | 6 (75) | 2 (25) |
| Frequency of PTC | Nil | 136 (84.5) | 25 (15.5) |  |  |  | 0.1903 |
| 1 PTC | 6 (85.7) | 1 (14.3) |
| 2 PTC | 0 (0) | 1 (100) |
| Surgical intervention for stricture | - | 141 (83.9) | 27 (16.1) | 0.8 | 0.8 | 0.9 | 1.0002 |
| + | 1 (100) | 0 (0) |
| HCV PCR at occurrence of stricture | Negative | 10 (66.7) | 5 (33.3) |  |  |  | 0.6603 |
| Below 200000 IU | 12 (80) | 3 (20) |
| 200000 to 2 million | 15 (78.9) | 4 (21.1) |
| More than 2 million | 6 (54.5) | 5 (45.5) |
| Antiviral treatment in relation to stricture | Not given | 21 (77.8) | 6 (22.2) |  |  |  | 0.5362 |
| Before stricture | 9 (64.3) | 5 (35.7) |
| After stricture | 4 (66.7) | 2 (33.3) |
| During occurrence of stricture | 9 (69.2) | 4 (30.8) |
| Admission related to BC | - | 85 (89.5) | 10 (10.5) | 2.5 | 1.1 | 5.9 | **0.028** |
| + | 57 (77) | 17 (23) |
| Frequency of admissions related to biliary complications | Nil | 85 (89.5) | 10 (10.5) |  |  |  | **0.0023** |
| 1-2 | 35 (87.5) | 5 (12.5) |
| ≥ 3 | 22 (64.7) | 12 (35.3) |
| Recurrent HCV | - | 116 (90.6) | 12 (9.4) | 5.6 | 2.3 | 13.3 | **< 0.001** |
| + | 26 (63.4) | 15 (36.6) |
| Resolution of recurrent HCV | - | 1 (25) | 3 (75) | 0.2 | 0.0 | 1.7 | 0.1302 |
| + | 25 (67.6) | 12 (32.4) |

1Pearson chi-squared test unless otherwise indicated.

2Fisher’s exact test.

3Chi-squared test for trend.

Data are presented as number (*n*) and percentage (%). OR: Odds ratio; LCL: Lower confidence limit; UCL: Lower confidence limit; ERCP: Endoscopic retrograde cholangiopancreatography; PTC: Percutaneous transhepatic cholangiography; PCR: Polymerase chain reaction; HCV: Hepatitis C virus; BC: Biliary complication.

**Table 7 Multivariable binary logistic regression model for prediction of chronic graft rejection**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | ***P* value** | **Odds ratio** | **95%CI** |
| Biliary infection | **0.001** | 4.301 | 1.97-8.224 |
| Early biliary infection | 0.061 | 1.105 | 0.89-1.20 |
| Frequency of biliary infection | **0.025** | 1.208 | 0.536-2.726 |
| Biliary stricture | **< 0.0001** | 3.882 | 4.056-9.952 |
| Need for ERCP | **0.02** | 2.91 | 1.85-7.97 |
| Frequency of ERCP | 0.074 | 1.098 | 0.99-1.114 |
| Number of stents | 0.62 | 1.22 | 0.57-2.42 |
| Admission related to BCs | 0.082 | 1.102 | 0.99-1.40 |
| Frequency of admission | 0.51 | 1.73 | 0.56-7.5 |
| Recurrent HCV | **0.032** | 3.11 | 1.97-8.07 |

CI: Confidence interval; ERCP: Endoscopic retrograde cholangiopancreatography; HCV: Hepatitis C virus; BC: Biliary complication.

**Table 8 Relation between biliary complications and graft failure**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **No graft failure (*n* = 149), *n* (%)** | **Graft failure (*n* = 20), *n* (%)** | **OR** | **CI** | ***P* value1** |
| **95% LCL** | **95% UCL** |
| Biliary leakage | - | 105 (92.1) | 9 (7.9) | 2.9 | 1.1 | 7.5 | **0.022** |
| + | 44 (80) | 11 (20) |
| Insertion of pigtail catheter | - | 144 (90) | 16 (10) | 7.2 | 1.8 | 29.6 | **0.0122** |
| + | 5 (55.6) | 4 (44.4) |
| Biliary infection | - | 68 (94.4) | 4 (5.6) | 3.4 | 1.1 | 10.5 | **0.029** |
| + | 81 (83.5) | 16 (16.5) |
| Frequency of biliary infection | Nil | 68 (94.4) | 4 (5.6) |  |  |  | **0.0213** |
| 1-2 Episodes | 71 (84.5) | 13 (15.5) |
| ≥ 3 Episodes | 10 (76.9) | 3 (23.1) |
| Early biliary infection | - | 73 (93.6) | 5 (6.4) | 2.9 | 1.0 | 8.3 | **0.043** |
| + | 76 (83.5) | 15 (16.5) |
| Biliary stricture | - | 98 (89.9) | 11 (10.1) | 1.6 | 0.6 | 4.0 | 0.345 |
| + | 51 (85) | 9 (15) |
| Frequency of biliary stricture | Nil | 98 (89.9) | 11 (10.1) |  |  |  | 0.1683 |
| 1-2 Episodes | 38 (88.4) | 5 (11.6) |
| ≥ 3 Episodes | 13 (76.5) | 4 (23.5) |
| Early biliary stricture | - | 137 (89) | 17 (11) | 2.0 | 0.5 | 7.9 | 0.3922 |
| + | 12 (80) | 3 (20.0) |
| Need for ERCP | - | 98 (89.9) | 11 (10.1) | 1.6 | 0.6 | 4.0 | 0.345 |
| + | 51 (85) | 9 (15.0) |
| Frequency of ERCP | Nil | 98 (89.9) | 11 (10.1) |  |  |  | 0.1883 |
| 1-2 ERCP | 37 (88.1) | 5 (11.9) |
| ≥ 3 ERCP | 14 (77.8) | 4 (22.2) |
| Number of stents introduced for stricture | Nil | 101 (90.2) | 11 (9.8) |  |  |  | 0.1363 |
| 1-2 Stents | 30 (88.2) | 4 (11.8) |
| ≥ 3 Stents | 18 (78.3) | 5 (21.7) |
| Need for PTC | - | 142 (88.2) | 19 (11.8) | 1.1 | 0.1 | 9.2 | 1.0002 |
| + | 7 (87.5) | 1 (12.5) |
| Frequency of PTC | Nil | 142 (88.2) | 19 (11.8) |  |  |  | 0.3743 |
| 1 PTC | 7 (100) | 0 (0) |
| 2 PTC | 0 (0) | 1 (100) |
| Surgical intervention for stricture | - | 148 (88.1) | 20 (11.9) | 0.9 | 0.8 | 0.9 | 1.0002 |
| + | 1 (100) | 0 (0) |
| HCV PCR at occurrence of stricture | Negative | 13 (86.7) | 2 (13.3) |  |  |  | 0.2923 |
| Below 200000 IU | 13 (86.7) | 2 (13.3) |
| 200000 to 2 million | 18 (94.7) | 1 (5.3) |
| More than 2 million | 7 (63.6) | 4 (36.4) |
| Antiviral treatment in relation to stricture | Not given | 24 (88.9) | 3 (11.1) |  |  |  | 0.8362 |
| Before stricture | 11 (78.6) | 3 (21.4) |
| After stricture | 5 (83.3) | 1 (16.7) |
| During occurrence of stricture | 11 (84.6) | 2 (15.4) |
| Admission related to BC | - | 85 (89.5) | 10 (10.5) | 1.3 | 0.5 | 3.4 | 0.551 |
| + | 64 (86.5) | 10 (13.5) |
| Frequency of admissions related to BC | Nil | 85 (89.5) | 10 (10.5) |  |  |  | 0.119 |
| 1-2 ERCP | 38 (95) | 2 (5) |
| ≥3 ERCP | 26 (76.5) | 8 (23.5) |
| Recurrent HCV infection | - | 118 (92.2) | 10 (7.8) | 3.8 | 1.5 | 10.0 | **0.0102** |
| + | 31 (75.6) | 10 (24.4) |
| Resolution of recurrent HCV | - | 0 (0) | 4 (100) | 6.2 | 3.0 | 12.8 | **0.0022** |
| + | 31 (83.8) | 6 (16.2) |

1Pearson chi-squared test unless otherwise indicated.

2Fisher’s exact test.

3Chi-squared test for trend.

Data are presented as number (*n*) and percentage (%). OR: Odds ratio; LCL: Lower confidence limit; UCL: Lower confidence limit; ERCP: Endoscopic retrograde cholangiopancreatography; PTC: Percutaneous transhepatic cholangiography; PCR: Polymerase chain reaction; HCV: Hepatitis C virus; BC: Biliary complication.

**Table 9 Multivariable binary logistic regression model for prediction of graft failure**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | ***P* value** | **Odds ratio** | **95%CI** |
| Biliary leakage | **0.021** | 1.82 | 1.34-5.57 |
| Insertion of pigtail catheter  | **0.010** | 3.76 | 1.45-11.83 |
| Biliary infection | **0.032** | 3.11 | 1.03-9.06 |
| Early biliary infection | 0.05 | 1.34 | 0.65-2.86 |
| Frequency of biliary infection | **0.001** | 2.52 | 1.28-4.91 |
| Nonresponse to HCV anti-viral therapy | **0.001** | 3.6 | 1.8-9.34 |
| Recurrent HCV | **0.001** | 3.56 | 1.86-10.71 |

CI: Confidence interval; HCV: Hepatitis C virus.

**Table 10 Relation between biliary complications and mortality**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **Survivors (*n* = 141), *n* (%)** | **Non-survivors (*n* = 28), *n* (%)** | **OR** | **CI** | ***P* value1** |
| **95% LCL** | **95% UCL** |
| Biliary leakage | - | 97 (85.1) | 17 (14.9) | 1.4 | 0.6 | 3.3 | 0.405 |
| + | 44 (80) | 11 (20) |
| Biliary infection | - | 60 (83.3) | 12 (16.7) | 1.0 | 0.4 | 2.2 | 1.0002 |
| + | 81 (83.5) | 16 (16.5) |
| Frequency of biliary infection | Nil | 60 (83.3) | 12 (16.7) |  |  |  | 0.9403 |
| 1-2 Episodes | 70 (83.3) | 14 (16.7) |
| ≥ 3 Episodes | 11 (84.6) | 2 (15.4) |
| Early biliary infection | - | 64 (82.1) | 14 (17.9) | 0.8 | 0.4 | 1.9 | 0.6552 |
| + | 77 (84.6) | 14 (15.4) |
| Biliary stricture | - | 89 (81.7) | 20 (18.3) | 0.7 | 0.3 | 1.7 | 0.4012 |
| + | 52 (86.7) | 8 (13.3) |
| Frequency of biliary strictures | Nil | 89 (81.7) | 20 (18.3) |  |  |  | 0.3963 |
| 1-2 Episodes | 37 (86) | 6 (14) |
| ≥ 3 Episodes | 15 (88.2) | 2 (11.8) |
| Early biliary stricture | - | 128 (83.1) | 26 (16.9) | 0.8 | 0.2 | 3.6 | 1.0002 |
| + | 13 (86.7) | 2 (13.3) |
| Need for ERCP | - | 89 (81.7) | 20 (18.3) | 0.7 | 0.3 | 1.7 | 0.4012 |
| + | 52 (86.7) | 8 (13.3) |
| Frequency of ERCP | Nil | 89 (81.7) | 20 (18.3) |  |  |  | 0.3753 |
| 1-2 ERCP | 36 (85.7) | 6 (14.3) |
| ≥ 3 ERCP | 16 (88.9) | 2 (11.1) |
| Number of stents introduced for stricture | Nil | 92 (82.1) | 20 (17.9) |  |  |  | 0.5203 |
| 1-2 Stents | 29 (85.3) | 5 (14.7) |
| ≥ 3 Stents | 20 (87) | 3 (13) |
| Need for PTC | - | 134 (83.2) | 27 (16.8) | 0.7 | 0.1 | 6.0 | 1.0002 |
| + | 7 (87.5) | 1 (12.5) |
| Frequency of PTC  | Nil | 134 (83.2) | 27 (16.8) |  |  |  | 0.6743 |
| 1 PTC | 7 (100) | 0 (0) |
| 2 PTC | 0 (0) | 1 (100) |
| Surgical intervention for stricture | - | 140 (83.3) | 28 (16.7) |  |  |  | 1.0002 |
| + | 1 (100) | 0 (0) |
| HCV PCR at occurrence of stricture | Negative | 12 (80) | 3 (20) |  |  |  | 0.8493 |
| Below 200 000 IU | 14 (93.3) | 1 (6.7) |
| 200000 to 2 million | 18 (94.7) | 1 (5.3) |
| More than 2 million | 8 (72.7) | 3 (27.3) |
| Antiviral treatment in relation to stricture | Not given | 23 (85.2) | 4 (14.8) |  |  |  | 1.0002 |
| Before stricture | 12 (85.7) | 2 (14.3) |
| After stricture | 5 (83.3) | 1 (16.7) |
| During occurrence of stricture | 12 (92.3) | 1 (7.7) |
| Admission related to BC | - | 75 (78.9) | 20 (21.1) | 0.5 | 0.2 | 1.1 | 0.0762 |
| + | 66 (89.2) | 8 (10.8) |
| Recurrent HCV | - | 108 (84.4) | 20 (15.6) | 1.3 | 0.5 | 3.2 | 0.5602 |
| + | 33 (80.5) | 8 (19.5) |
| Resolution of recurrent HCV (*n* = 41) | - | 0 (0) | 4 (9.7) | 9.3 | 3.7 | 23.3 | **0.0012** |
| + | 33 (80.4) | 4 (9.7) |

1Pearson chi-squared test unless otherwise indicated.

2Fisher’s exact test.

3Chi-squared test for trend.

Data are presented as number (*n*) and percentage (%). OR: Odds ratio; LCL: Lower confidence limit; UCL: Lower confidence limit; ERCP: Endoscopic retrograde cholangiopancreatography; PTC: Percutaneous transhepatic cholangiography; PCR: Polymerase chain reaction; HCV: Hepatitis C virus; BC: Biliary complication.